Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
EQS-News: Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements ...
Mainz Biomed Regains Compliance With Nasdaq Listing Rules
Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's ...
Mainz BioMed NV: Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...
PharmiWeb3d
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
BERKELEY, US – MAINZ, Germany – January 27, 2025 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...
Investing3d
Mainz Biomed regains Nasdaq compliance with equity rule
BERKELEY, Calif. and MAINZ, Germany - Mainz Biomed NV (NASDAQ:MYNZ), a company focused on early cancer detection diagnostics, has announced its return to compliance with Nasdaq's stockholders ...